Yaara Oren, PhD

Despite a favorable initial response to therapy, 30% of cancer patients will experience relapse and die within five years of diagnosis. It is not clear why some cancer cells that initially respond to treatment can ultimately dodge it and refuel tumor growth. Dr. Oren’s team is developing a new tool to track and study cells that escape post-treatment senescence, in which cells stop dividing and proliferating, thus preventing tumor growth. The study should help spur the development of new therapies that delay or even prevent recurrent disease.  

View Grant Recipient Profile